Studies have shown that PD-1 mAb and anti-VEGFR2 agent combination treatment could promote tumor vessel normalization and induce high endothelial venules (HEVs), which promoted lymphocyte infiltration and activity through the activation of lymphotoxin β receptor (LTβR) signaling (15). The gene discussed is LTBR; the disease is neoplasm.